![[del.icio.us]](http://pennystockdd.com/wp-content/plugins/bookmarkify/delicious.png)
![[Digg]](http://pennystockdd.com/wp-content/plugins/bookmarkify/digg.png)
![[Faves]](http://pennystockdd.com/wp-content/plugins/bookmarkify/faves.png)
![[LinkedIn]](http://pennystockdd.com/wp-content/plugins/bookmarkify/linkedin.png)
![[Reddit]](http://pennystockdd.com/wp-content/plugins/bookmarkify/reddit.png)
![[StumbleUpon]](http://pennystockdd.com/wp-content/plugins/bookmarkify/stumbleupon.png)
![[Technorati]](http://pennystockdd.com/wp-content/plugins/bookmarkify/technorati.png)
Bank of America Corp. (BAC: News ) is rising 1 percent to $15.35. The company agreed to pay $335 million as settlement for charges related to alleged discriminatory lending practices by its subsidiary Countrywide Financial
Regards,
Don
Tag: VVUS
Yahoo! Inc. (YHOO: News ) is rising over 1 percent to $14.72 amid revived rumors about the company being a takeover target. Daniel Loeb’s Third Point LLC urged the company’s Co-founder and Director Jerry Yang to push for further leadership changes, and alleged that Chairman Roy Bostock has been a destroyer of company value.
Pier 1 Imports, Inc. (PIR: News ) is rising over 2 percent to $11.95 as it reported higher earnings for its second quarter. Net sales improved 9.6 percent. The company specified that its growth plan is firmly on track.
Regards,
Don
MediciNova, Inc. (NASDAQ:MNOV) witnessed the correction of 25.28% and closed at $2.66 whereas overall traded volume stood at 1.68 million shares for the day. The current market price is 39.98% less than its last 50 days simple moving average. The share price is likely to move by 0.70 times against 1 point change in market index.
VIVUS, Inc. (NASDAQ:VVUS) went down by 0.46% to close at $6.54 with total traded volume of 1.30 million shares in the last trading day. Its outstanding share stood at 81.89 million and its total market capitalization ended at $535.56 million.
Novavax, Inc. (NASDAQ:NVAX) closed at $2.56 after dropping by 3.76% whereas traded volume stood at 1.10 million shares for the day. The share price is highly reactive to market index as its beta value stands at 2.25 times till its last trading session.
(Read the Rest of the Article…)
More on this topic
(What's this?)
VIVUS Inc (NASDAQ: VVUS) Q2 2011 Price Target
(Value Investing Experiments, 3/7/11)
BioWatch: VIVUS & Orexigen Looking More FDA-Favorable (VVUS, OREX, ARNA)
(Wall Street Sector Selector, 4/4/11)
(VVUS) Vivus’ Qnexa Weight Loss Candidate Reports Encouraging Study Data
(Stock Blog Hub, 4/7/11)
(VVUS) Vivus’ Qnexa Safety and Efficacy Information Published
(Stock Blog Hub, 4/13/11)
Cell Therapeutics, Inc. (NASDAQ:CTIC) jumped up by 6.67% to close at $0.32 with overall traded volume of 42.90 million shares in the last trading day. The current market price is 4.13% less than its last 50 days simple moving average. The share price is highly sensitive as its beta value stands at 5.83 times till its last trading session.
Sequenom, Inc. (NASDAQ:SQNM) moved up by 2.79% and closed at $5.88 whereas total traded volume stood at 2.63 million shares for the day as compare to its average volume stood at 2.69 million. The company maintains strong short term liquidity position with current ratio of 7.80 times.
Dendreon Corporation (NASDAQ:DNDN) closed at $34.61 after surging by 2.70% with traded volume of 5.04 million shares in the last trading day. Its outstanding shares stood at 145.52 million. Its total market capitalization arrived at $5.04 billion.
(Read the Rest of the Article…)
VIVUS, Inc. (NASDAQ:VVUS) dropped by 9.36% and closed at $6.39 whereas overall traded volume stood at 8.54 million shares for the day. Its outstanding shares stood at 81.89 million. Its total market capitalization arrived at $523.28 million.
Cerus Corporation (NASDAQ:CERS) went down by 13.69% to close at $2.90 with total traded volume of 2.75 million shares in the last trading day. The share price is highly sensitive as its beta value stands at 2.23 times till its last trading session. The current market price is 7.60% less than its last 50 days simple moving average.
(Read the Rest of the Article…)
VIVUS, Inc. (NASDAQ:VVUS) dropped by 16.20% and closed at $8.74 whereas overall traded volume stood at 10.38 million shares for the day. The company maintains strong short term liquidity position with current ratio of 8.33 times. The share price is likely to move by 0.82 times against 1 point change in market index.
Acorda Therapeutics Inc. (NASDAQ:ACOR) witnessed the correction of 13.87% to close at $23.97 with total traded volume of 8.52 million shares in the last trading day. The current market price is 11.72% less than its last 50 days simple moving average. Its total market capitalization stood at $936.75 million.
Synaptics, Incorporated (NASDAQ:SYNA) closed at $28.55 after plunging by 10.92% whereas traded volume stood at 5.15 million shares for the day. The RSI value of 38.96 times depicts that the current shares value is in oversold level. Its price to earnings ratio stands at 16.41 times till its last trading session.
(Read the Rest of the Article…)
More on this topic
(What's this?)
Synaptics Inc. (NASDAQ: SYNA): Q2 Earnings Preview 2011
(Stock Wizard, 1/20/11)
MannKind: Deja Vu for the FDA and Afrezza
(Investment Underground » Page n..., 12/29/10)
VIVUS Inc (NASDAQ: VVUS) Q2 2011 Price Target
(Value Investing Experiments, 3/7/11)
Stocks In Focus: MNKD, WEN, CYTX
(Stock Wizard, 1/20/11)
Posted on September 22nd, 2010 Tony No comments
Energizer Holdings , Inc. (NYSE:ENR) shares went up by 1.33% to $70.94 this morning, after it was upgraded by BMO Capital from Market Perform to Outperform this morning, also raising its price target on the stock from $72 to $90. The stock today also hits a new 52-week high at $72.60.
VIVUS, Inc. (NASDAQ:VVUS) spurted 5.04% at $7.08 after Canaccord Genuity upgrades the stock from Hold to Buy and raised their price target from $6 to $10. The stock has jumped 11.50% in the last one week trade. (Read the Rest of the Article…)
Regards,
Don
Regards,
Don
By Lisa LaMotta Sep 21, 2010 1:45 pm
Less than a week after Arena’s lorcaserin wasn’t recommended for approval, the competition has released new data to support its own obesity treatment.
Regards,
Don
More on this topic
(What's this?)
Vivus Soars On Study Results Despite Analyst Pessimism (VVUS, ARNA, OREX, CVM, ONTY)
(tickerspy.com, 9/21/10)
Obesity Drug Stocks
(Wealth Daily, 7/19/10)
Arena Tumbles Ahead of FDA Review (ARNA, VVUS, OREX)
(tickerspy.com, 9/14/10)
Options Trade for FDA Panel Decision – VVUS
(, 7/1/10)
Stock Alert for VIVUS Inc. (VVUS)
VIVUS Inc. (VVUS) is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company’s product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in phase III clinical trials for obesity and in phase II clinical trials for diabetes. The Company’s late-stage investigational product pipeline includes Qnexa for treating obesity, for which two of the phase III studies are in process and one phase III study has been completed; Qnexa for treating diabetes, for which a one-year phase II study has been completed; Avanafil, which is being developed for the treatment of erectile dysfunction, for which phase III studies are in process; and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a phase II study has been completed
Regards,
Don
More on this topic
(What's this?)
Vivus Soars On Study Results Despite Analyst Pessimism (VVUS, ARNA, OREX, CVM, ONTY)
(tickerspy.com, 9/21/10)
Arena Tumbles Ahead of FDA Review (ARNA, VVUS, OREX)
(tickerspy.com, 9/14/10)
Options Trade for FDA Panel Decision – VVUS
(, 7/1/10)
Shares of Vivus up on anticipation of phase 3 data on new ED drug (VVUS)
(AlphaNinja, 5/28/10)
